*GG*
senior member
- Messages
- 6,389
- Location
- Concord, NH
Welcome to Phoenix Rising!
Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of and finding treatments for complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia (FM), long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.
To become a member, simply click the Register button at the top right.
At the Open Medicine Institute, I was started at 4.5mg per day and later gradually increased to 9mg. I've been on 9mg for about a year.From my ME-doctor I learnt that LDN might work, or not, due to my genetics. I was also told to take it in the morning, to avoid insomnia. I started with 0.5 mg´s and increased the dose slowly over some months until 4.5 mg. If it hadn´t worked then, it shouldn´t work for me. There shouldn´t be any reason to increase the dose further according to his experience. FWIW.
Interesting to hear about quite another dosing and I´m glad to hear that it works so well for you. Your example may inspire to chose other dosages to get a better result.At the Open Medicine Institute, I was started at 4.5mg per day and later gradually increased to 9mg. I've been on 9mg for about a year.
So I've never been on a dose of LDN less than 4.5mg.
I find LDN the most beneficial treatment I've found. Stumbling and breathing issues are no longer significantly limiting. Body and joint pain have never been an issue for me (except for a 5 year period ending 20 years ago).
This 2010 study of MS patients also used 4.5mg.Interesting to hear about quite another dosing and I´m glad to hear that it works so well for you. Your example may inspire to chose other dosages to get a better result.
(note: I had to use the Firefox browser to get this link to display properly).http://onlinelibrary.wiley.com/doi/10.1002/ana.22006/abstract
Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis
Objective
To evaluate the efficacy of 4.5mg nightly naltrexone on the quality of life of multiple sclerosis (MS) patients.
Methods
This single-center, double-masked, placebo-controlled, crossover study evaluated the efficacy of 8 weeks of treatment with 4.5mg nightly naltrexone (low-dose naltrexone, LDN) on self-reported quality of life of MS patients.
Results
Eighty subjects with clinically definite MS were enrolled, and 60 subjects completed the trial. Ten withdrew before completing the first trial period: 8 for personal reasons, 1 for a non–MS-related adverse event, and 1 for perceived benefit. Database management errors occurred in 4 other subjects, and quality of life surveys were incomplete in 6 subjects for unknown reasons. The high rate of subject dropout and data management errors substantially reduced the trial's statistical power. LDN was well tolerated, and serious adverse events did not occur. LDN was associated with significant improvement on the following mental health quality of life measures: a 3.3-point improvement on the Mental Component Summary score of the Short Form-36 General Health Survey (p = 0.04), a 6-point improvement on the Mental Health Inventory (p < 0.01), a 1.6-point improvement on the Pain Effects Scale (p =.04), and a 2.4-point improvement on the Perceived Deficits Questionnaire (p = 0.05).
Interpretation
LDN significantly improved mental health quality of life indices. Further studies with LDN in MS are warranted. ANN NEUROL 20